stemspantm serum-free expansion medium (STEMCELL Technologies Inc)
90
Structured Review
STEMCELL Technologies Inc
stemspantm serum-free expansion medium
Stemspantm Serum Free Expansion Medium, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspantm+serum-free+expansion+medium/stemspantm+serum+free+expansion+medium++sfem+/pm40597397-103-7-12
Average 90 stars, based on 1 article reviews
Stemspantm Serum Free Expansion Medium, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stemspantm+serum-free+expansion+medium/stemspantm+serum+free+expansion+medium++sfem+/pm40597397-103-7-12
Average 90 stars, based on 1 article reviews
stemspantm serum-free expansion medium - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Cell Culture:Article Title: Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of ITGA2B Promoter-Driven BDDF8 Gene in Hemophilia A Article Snippet: The sorted CD34 positive iHPCs were cultured in Article Title: Synthetic guide molecules, compositions and methods relating thereto Article Snippet: Human CD34+ cells were counted, centrifuged to a pellet and resuspended in P3 Nucleofection Buffer, then dispensed to each well of a 96-well Nucleocuvette Plate that was pre-filled with Article Title: Induction of arterial-type of hemogenic endothelium (AHE) and enhancement of T cell production from PSCs through overexpression of ETS factors or modulating MAPK/ERK signalling pathways Article Snippet: HB-CFCs were detected using the semisolid colony-forming serum-free medium (CF-SFM) containing 40% Article Title: Deletion of p18 INK4c enhances both osteogenesis and hematopoietic supportive capacity of bone marrow mesenchymal stromal cells. Article Snippet: WTC57 c-Kit+ (1 × 105) cells in StemSpanTM Serum-Free Expansion Medium (SFEM, Article Title: IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-κB, inhibited by methoxyluteolin. Article Snippet: For the first 6 weeks, CD34+ progenitor cells were cultured in StemSpanTM Serum-Free Expansion medium (Catalog # 09655, StemCell Technologies) supplemented with 1% penicillin/streptomycin (Catalog # 15140122, Thermo Fisher Scientific) 50 ng/ml Article Title: Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia. Article Snippet: Leukemic stem cells (LSCs) are a major cause of treatment failure and recurrence of acute myeloid leukemia (AML).. Targeting LSC is essential to developing a potential cure for patients with relapsed/refractory AML.. Here we investigated the effect of aryl hydrocarbon receptor (AhR) signaling on AML stem/progenitor proportion and examined the combined effect of AhR agonist and tyrosine kinase inhibitor. Article Title: Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival. Article Snippet: The clinical management of pediatric acute myeloid leukemia (AML) is still challenging and identification of drugs that can enhance the efficacy of standard of care is a potential therapeutic strategy.. We show that pamidronate, a FDA-approved drug used for bone disorders, is an attractive candidate for AML treatment.. Pamidronate inhibits proliferation and induces apoptosis of AML cells regardless of cellular and genetic heterogeneity. Article Title: Engineered mesenchymal stem cell exosomes loaded with miR-34c-5p selectively promote eradication of acute myeloid leukemia stem cells. Article Snippet: AML CD34+ cells were maintained in Recombinant:Article Title: Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of ITGA2B Promoter-Driven BDDF8 Gene in Hemophilia A Article Snippet: The sorted CD34 positive iHPCs were cultured in Article Title: Synthetic guide molecules, compositions and methods relating thereto Article Snippet: Human CD34+ cells were counted, centrifuged to a pellet and resuspended in P3 Nucleofection Buffer, then dispensed to each well of a 96-well Nucleocuvette Plate that was pre-filled with Article Title: Induction of arterial-type of hemogenic endothelium (AHE) and enhancement of T cell production from PSCs through overexpression of ETS factors or modulating MAPK/ERK signalling pathways Article Snippet: HB-CFCs were detected using the semisolid colony-forming serum-free medium (CF-SFM) containing 40% Article Title: Deletion of p18 INK4c enhances both osteogenesis and hematopoietic supportive capacity of bone marrow mesenchymal stromal cells. Article Snippet: WTC57 c-Kit+ (1 × 105) cells in StemSpanTM Serum-Free Expansion Medium (SFEM, Article Title: IL-33 stimulates human mast cell release of CCL5 and CCL2 via MAPK and NF-κB, inhibited by methoxyluteolin. Article Snippet: For the first 6 weeks, CD34+ progenitor cells were cultured in StemSpanTM Serum-Free Expansion medium (Catalog # 09655, StemCell Technologies) supplemented with 1% penicillin/streptomycin (Catalog # 15140122, Thermo Fisher Scientific) 50 ng/ml Article Title: Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia. Article Snippet: Leukemic stem cells (LSCs) are a major cause of treatment failure and recurrence of acute myeloid leukemia (AML).. Targeting LSC is essential to developing a potential cure for patients with relapsed/refractory AML.. Here we investigated the effect of aryl hydrocarbon receptor (AhR) signaling on AML stem/progenitor proportion and examined the combined effect of AhR agonist and tyrosine kinase inhibitor. Article Title: Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival. Article Snippet: The clinical management of pediatric acute myeloid leukemia (AML) is still challenging and identification of drugs that can enhance the efficacy of standard of care is a potential therapeutic strategy.. We show that pamidronate, a FDA-approved drug used for bone disorders, is an attractive candidate for AML treatment.. Pamidronate inhibits proliferation and induces apoptosis of AML cells regardless of cellular and genetic heterogeneity. Article Title: Engineered mesenchymal stem cell exosomes loaded with miR-34c-5p selectively promote eradication of acute myeloid leukemia stem cells. Article Snippet: AML CD34+ cells were maintained in |